- Company
- Eisai strengthened Pariet's sales, collaborated with Yuhan
- by Nov 6, 2020 06:25am
- Eisai strengthened the collaboration of Pariet (Rabeprazole) with a domestic company of PPI. The joint sales were expanded to Pariet 10·20mg following low-dose Pariet 5mg. According to the pharmaceutical industry on the 3rd, Yuhan recently signed a joint sale contract with Eisai for Pariet 10·20mg, and started supplying the product fro
- Company
- Lilly implements ERP for the sales department
- by Nov 5, 2020 11:03am
- On the 4th, Lilly Korea announced the implementation of ERP to all employees of the sales department. It is known that the ERP compensation condition adds 8 months to twice the number of years of service, and provides annual consolation money. Although the exact size is undecided, it is intended for all employees of the sales organizati
- Company
- Zuellig Pharma union reports company’s abusive practice
- by An, Kyung-Jin Nov 5, 2020 06:41am
- The management and labor union dispute in Zuellig Pharma Korea’s subsidiary Zuellig Pharma Solutions Service Korea seems to be intensifying fast. According to the pharmaceutical industry sources on Nov. 3, Korea Democratic Pharmaceutical Union has recently reported Zuellig Pharma Solutions Service Korea management for their unfair lab
- Company
- Gilead, registered 6 patents for Remdesivir in Korea
- by Kim, Jin-Gu Nov 5, 2020 06:40am
- It is confirmed that Gilead recently registered a patent related to Remdesivir (Veklury) in Korea. Remdesivir is currently the only drug approved for the treatment of COVID-19. In Korea, it was supplied in earnest from last July. According to the MFDS and the KIPO on the 3rd, Gilead registered six patents related to Remdesivir in the dome
- Company
- MSD Korea appoints Seongpil Kim as executive director
- by Nov 5, 2020 06:40am
- MSD Korea (CEO Kevin Peters) announced on the 1st that it had appointed Kim Seong-pil (43 years old), executive director of the anticancer drug division. In December 2018, the new executive director of Seongpil Kim joined MSD Korea as the 'Commercial Operations Lead', which led to double-digit growth. He has also contributed significan
- Company
- Multinational companies rush to appoint new CEOs
- by Eo, Yun-Ho Nov 5, 2020 06:40am
- Multiple Korean subsidiaries of multinational pharmaceutical companies are reporting their news of newly appointed top executives. Just in the latter half of the year, six companies have welcomed their new leaders. According to pharmaceutical industry sources, Sanofi Pasteur Korea, Galderma Korea, Ono Pharma Korea, MSD Korea, Organ
- Company
- Soliris competitor Roche’s Enspryng readies for South Korea
- by Eo, Yun-Ho Nov 4, 2020 06:09am
- Apparently, Enspryng, a Soliris (eculizumab) competitor, is making a move to enter the South Korean market. The pharmaceutical industry sources reported Roche Korea has recently submitted an approval application on a neuromyelitis optica spectrum disorder (NMOSD) treatment Enspryng (satralizumab) to the Ministry of Food and Drug Safety (
- Company
- AstraZeneca objected to the second judgment of Forxiga
- by Kim, Jin-Gu Nov 4, 2020 06:08am
- AstraZeneca lost the second trial of Forxiga's material patent. And AstraZeneca announced that it would appeal to the Supreme Court. AstraZeneca said in a separate statement on the 30th that it disobeyed the judgment of the Patent Court of Korea on the 29th. The Patent Court of Korea sided with 19 companies including Kukje Pharma in a law
- Company
- Opdivo resumes indication expansion in NSCLC as first-line
- by Eo, Yun-Ho Nov 3, 2020 05:58am
- The pharmaceutical industry sources reported Ono Pharmaceutical and Bristol Myers Squibb (BMS) have recently submitted an application to expand indication on a programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitor Yervoy
- Company
- The Korean MSD union opposes the spin-off of Organon
- by Nov 3, 2020 05:58am
- MSD Korea's labor union begins full-scale dispute activities ahead of the spin-off of Organon. The representative group for bargaining of MSD Korea and the MSD branch of the Korea Democratic Pharmaceutical Union (KDPU) held votes for and against the industrial action for each member on the 28th to 29th. As a result, both unions approved t
